Disease-related characteristics including classification of cytogenetics and risk group stratification were extrapolated from the Children’s Oncology Group criteria. Negative bone marrow (BM) result was defined as per institutional parameters for negative minimal residual disease (MRD) below 0.1-0.01% for lymphoblastic leukemia and M1 marrow for myelocytic leukemia. Complete response (CR) was defined as the attainment of negative BM after treatment with complete or partial hematological recovery. Complete hematological recovery was defined as attainment of absolute neutrophil count ≥ 0.75 × 109 and platelet count ≥ 75 × 109. Partial hematological recovery was defined as not meeting absolute neutrophil count and/or platelet count recovery threshold. Adverse events were graded as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
OS was defined as survival time in months from the date of initial diagnosis to last follow-up or death. Death from any cause was considered as an event. The last follow-up on the patients was carried out in February 2022.
OS was defined as survival time in months from the date of initial diagnosis to last follow-up or death. Death from any cause was considered as an event. The last follow-up on the patients was carried out in February 2022.
